Literature DB >> 22009190

Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.

Eileen B Lawson1, Jerry C Wu, R Michael Baldwin, Magnus Ingelman-Sundberg, Staffan Rosenborg, Dong-Seok Yim, Ophelia Q P Yin, Edmund V Capparelli, Joseph D Ma.   

Abstract

PURPOSE: To develop a limited sampling strategy (LSS) to predict area under the concentration-time curve (AUC) ratios of omeprazole (AUC(OPZ)) to its metabolites 5-hydroxyomeprazole (AUC(5OH)) and omeprazole sulfone (AUC(SUL)) as phenotyping parameters for cytochrome P450 (CYP) 2C19 and 3A.
METHODS: Data were obtained from 37 (4 women) Caucasian, Chinese, and Korean healthy adults from three published studies. The AUC(OPZ), AUC(5OH), and AUC(SUL) were calculated via noncompartmental analysis. Observed AUC(OPZ, OBS)/AUC(5OH, OBS) and AUC(OPZ, OBS)/AUC(SUL, OBS) were determined. Plasma concentrations of omeprazole, 5-hydroxyomeprazole, and omeprazole sulfone at 1, 1.5, 2, 3, 4, 6, and 8 h post-dose were used to generate limited sampling strategy (LSS) models to predict AUC(OPZ,PRE)/AUC(5OH,PRE) and AUC(OPZ,PRE/)AUC(SUL,PRE). Bias and precision were assessed via percentage mean prediction error (%MPE) and percentage mean absolute error (%MAE), with acceptable limits being <15%.
RESULTS: For CYP2C19, the AUC(OPZ,OBS)/AUC(5OH,OBS) was [mean ± standard deviation (SD)] 2.10 ± 1.63. Five LSS models of AUC(OPZ,PRE)/AUC(5OH,PRE) were generated, but none met the bias or precision criteria. Upon stratification by CYP2C19 genotype and ethnicity, a three-timepoint (at 1, 2, and 4 h) LSS model accurately predicted AUC(OPZ)/AUC(5OH) in Caucasian CYP2C19*1/*1 subjects. For CYP3A, AUC(OPZ,OBS)/AUC(SUL,OBS) (mean ± SD) was 1.79 ± 0.67. All LSS models had unacceptable %MAE, even when stratified by CYP2C19 genotype and ethnicity.
CONCLUSIONS: A LSS model to predict AUC(OPZ)/AUC(5OH), and thus CYP2C19 activity, was generated for Caucasian CYP2C19*1/*1 subjects. However, additional model validation is needed prior to general use. LSS models to predict AUC(OPZ)/AUC(SUL), and thus CYP3A activity, were not possible, even upon stratification by CYP2C19 genotype and ethnicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009190     DOI: 10.1007/s00228-011-1136-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

1.  Limited-sampling strategy models for estimating the area under the plasma concentration-time curve for amlodipine.

Authors:  G Suarez-Kurtz; F L Vicente; C G Ponte; V L Buy; C J Struchiner
Journal:  Eur J Clin Pharmacol       Date:  1999-11       Impact factor: 2.953

2.  Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction.

Authors:  Héctor M González; Elba M Romero; Teresa de J Chavez; A Aaron Peregrina; Víctor Quezada; Carlos Hoyo-Vadillo
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-25       Impact factor: 3.205

Review 3.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period.

Authors:  Binu S Mathew; Denise H Fleming; Vellaichamy M Annapandian; Samuel Prasanna; Chennaveera G Prasanna; Sujith J Chandy; George T John
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

6.  No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.

Authors:  K Laine; G Tybring; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

7.  The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.

Authors:  Yukio Ishizawa; Norio Yasui-Furukori; Takenori Takahata; Mutsuo Sasaki; Tomonori Tateishi
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.

Authors:  K Herrlin; A Y Massele; M Jande; C Alm; G Tybring; Y A Abdi; A Wennerholm; I Johansson; M L Dahl; L Bertilsson; L L Gustafsson
Journal:  Clin Pharmacol Ther       Date:  1998-10       Impact factor: 6.875

9.  Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.

Authors:  Myong-Jin Kim; Joseph S Bertino; Andrea Gaedigk; Yanhua Zhang; Edward M Sellers; Anne N Nafziger
Journal:  Clin Pharmacol Ther       Date:  2002-08       Impact factor: 6.875

10.  Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

Authors:  Siwaporn Chainuvati; Anne N Nafziger; J Steven Leeder; Andrea Gaedigk; Gregory L Kearns; Edward Sellers; Yanhua Zhang; Angela D M Kashuba; Elizabeth Rowland; Joseph S Bertino
Journal:  Clin Pharmacol Ther       Date:  2003-11       Impact factor: 6.875

View more
  3 in total

1.  A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.

Authors:  Gary Ginsberg; Suryanarayana V Vulimiri; Yu-Sheng Lin; Jayaram Kancherla; Brenda Foos; Babasaheb Sonawane
Journal:  J Toxicol Environ Health A       Date:  2017-09-11

2.  Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults.

Authors:  Swan Lin; Mina Nikanjam; Edmund V Capparelli; Alessandro Allegrini; Daniele Pavone; Dong-Seok Yim; Muhammad M Hammami; Joseph S Bertino; Anne N Nafziger; Yoo-Sin Park; Ju-Seop Kang; Ophelia Q Yin; Joseph D Ma
Journal:  Ther Drug Monit       Date:  2018-12       Impact factor: 3.681

3.  Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.

Authors:  Lynda J Haberer; Iain McSherry; Anna Cargill; Linda McCarthy
Journal:  Eur J Clin Pharmacol       Date:  2013-10-08       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.